Cargando…

Antiviral Treatments Eliminate the Adverse Impacts of High Baseline HBV Loads on the Survival of HBV-Related HCC Patients

BACKGROUND: In consideration of no standard exclusion criteria for hepatitis B virus (HBV) loads in hepatocellular carcinoma (HCC)-related clinical trials, this study aimed to investigate the prevalence of HBV-related exclusion criteria among current clinical trials and evaluate whether antiviral tr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Zili, Sun, Xuqi, Mei, Jie, Hu, Zhiwen, Yang, Ziliang, Hou, Jingyu, Fu, Yizhen, Wang, Xiaohui, Chen, Minshan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9034869/ https://www.ncbi.nlm.nih.gov/pubmed/35469289 http://dx.doi.org/10.2147/JHC.S363123

Ejemplares similares

Baseline HBV Loads Do Not Affect the Prognosis of Patients with Hepatocellular Carcinoma Receiving Anti-Programmed Cell Death-1 Immunotherapy
por: Sun, Xuqi, et al.
Publicado: (2020)

MicroRNAs Associated With HBV Infection And HBV-related HCC
por: Xie, Kun-Lin, et al.
Publicado: (2014)

HBV-HCC treatment with mRNA electroporated HBV-TCR T cells
por: Tan, Anthony T, et al.
Publicado: (2021)

Increasing antiviral treatment uptake improves survival in patients with HBV-related HCC
por: Hui, Vicki Wing-Ki, et al.
Publicado: (2020)

Epigenetic regulation of HBV-specific tumor-infiltrating T cells in HBV-related HCC
por: You, Maojun, et al.
Publicado: (2023)

Development and Validation of Prognostic Nomograms for Hepatocellular Carcinoma After Hepatectomy Based on Inflammatory Markers
por: Hu, Zili, et al.
Publicado: (2022)

HBV genome-enriched single cell sequencing revealed heterogeneity in HBV-driven hepatocellular carcinoma (HCC)
por: Wang, Wenhui, et al.
Publicado: (2022)

HBV-Induced Immune Imbalance in the Development of HCC
por: Chen, Yongyan, et al.
Publicado: (2019)

Interaction between baseline HBV loads and the prognosis of patients with HCC receiving anti-PD-1 in combination with antiangiogenic therapy undergoing concurrent TAF prophylaxis
por: Hu, Xiaoyun, et al.
Publicado: (2022)

Deep sequencing of HBV pre-S region reveals high heterogeneity of HBV genotypes and associations of word pattern frequencies with HCC
por: Bai, Xin, et al.
Publicado: (2018)

Human MAIT cells endowed with HBV specificity are cytotoxic and migrate towards HBV-HCC while retaining antimicrobial functions
por: Healy, Katie, et al.
Publicado: (2021)

HBV‐integrated local genomic alterations reveal multicentric independent occurrences of multifocal HCC
por: Zou, Hao, et al.
Publicado: (2023)

Viral integration drives multifocal HCC during the occult HBV infection
por: Chen, Xiao-Ping, et al.
Publicado: (2019)

Pathological Pattern of Intrahepatic HBV in HCC is Phenocopied by PDX-Derived Mice: a Novel Model for Antiviral Treatment
por: Liu, Jiao, et al.
Publicado: (2019)

Effects of antiviral therapy on post-hepatectomy HBV reactivation and liver function in HBV DNA-negative patients with HBV-related hepatocellular carcinoma
por: Gong, Wen-Feng, et al.
Publicado: (2017)

Serum Iron Levels Decreased in Patients with HBV-Related Hepatocellular Carcinoma, as a Risk Factor for the Prognosis of HBV-Related HCC
por: Wei, Yanyan, et al.
Publicado: (2018)

Immunological alterations after immunotherapy with short lived HBV‐TCR T cells associates with long‐term treatment response in HBV‐HCC
por: Tan, Anthony Tanoto, et al.
Publicado: (2021)

The HBV Specially-Related Long Noncoding RNA HBV-SRL Involved in the Pathogenesis of Hepatocellular Carcinoma
por: Zhang, Cunzhen, et al.
Publicado: (2022)

TLR3 Plays Significant Roles against HBV-Associated HCC
por: Chen, Xiao-lan, et al.
Publicado: (2015)

Plasma lipids, tumor parameters and survival in HCC patients with HBV and HCV
por: Akkiz, H, et al.
Publicado: (2020)

Sorafenib in the Treatment of Virus-Related HCC: Differences Between HCV and HBV
por: De Matteis, Serena, et al.
Publicado: (2021)

Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients
por: Sun, Xuqi, et al.
Publicado: (2021)

Effects of transarterial chemoembolization combined with antiviral therapy on HBV reactivation and liver function in HBV-related hepatocellular carcinoma patients with HBV-DNA negative
por: Wang, Kai, et al.
Publicado: (2018)

Antiviral therapy of chronic HBV infection in pregnancy
por: Nikolajuk-Stasiuk, Julita, et al.
Publicado: (2016)

Correction to: Viral integration drives multifocal HCC during the occult HBV infection
por: Chen, Xiao-Ping, et al.
Publicado: (2019)

Molecular Signature and Immune Landscape of HCV-Associated Hepatocellular Carcinoma (HCC): Differences and Similarities with HBV-HCC
por: De Battista, Davide, et al.
Publicado: (2021)

HBV‐RNA Co‐amplification May Influence HBV DNA Viral Load Determination
por: Maasoumy, Benjamin, et al.
Publicado: (2020)

HBV Induced HCC: Major Risk Factors from Genetic to Molecular Level
por: Ayub, Ambreen, et al.
Publicado: (2013)

Serum GGT/ALT ratio predicts vascular invasion in HBV-related HCC
por: Zhao, Zhifeng, et al.
Publicado: (2021)

Tenofovir vs Entecavir Among Patients With HBV-Related HCC After Resection
por: Li, Pengpeng, et al.
Publicado: (2023)

Dynamic changes of HBV markers and HBV DNA load in infants born to HBsAg(+) mothers: can positivity of HBsAg or HBV DNA at birth be an indicator for HBV infection of infants?
por: Chen, Tianyan, et al.
Publicado: (2013)

The Dynamic Role of NK Cells in Liver Cancers: Role in HCC and HBV Associated HCC and Its Therapeutic Implications
por: Sajid, Muhammad, et al.
Publicado: (2022)

Tenofovir is superior to entecavir in reducing HCC for patients with HBV-related compensated cirrhosis at high HCC risk scores
por: Huang, Yan, et al.
Publicado: (2022)

Enhanced antiviral and antifibrotic effects of short hairpin RNAs targeting HBV and TGF-β in HBV-persistent mice
por: Ye, Lei, et al.
Publicado: (2017)

1248. Relationship Between ALT and New HBV Biomarkers in HBV/HIV Coinfected Persons Started on Antiviral Therapy
por: Rouster, Susan D, et al.
Publicado: (2022)

Glucocorticoids and Antivirals for HBV Reactivation in Onco-Hematologic Patients.
por: Marzano, Alfredo, et al.
Publicado: (2010)

The Role of Antiviral Therapy for HBV-Related Hepatocellular Carcinoma
por: Yu, Liang-He, et al.
Publicado: (2011)

Efficacy of Adjuvant Transarterial Chemoembolization Combined Antiviral Therapy for HBV-Related HCC with MVI after Hepatic Resection: A Multicenter Study
por: Tang, Yupeng, et al.
Publicado: (2022)

Problems of Long Survival Following Surgery in Patients with NonBNonC-HCC: Comparison with HBV and HCV Related-HCC
por: Hiwatashi, Kiyokazu, et al.
Publicado: (2015)

The necroptosis related gene LGALS3 can be used as a biomarker for the adverse progression from chronic HBV infection to HCC
por: Dong, Jianming, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_urrao65ts4qdmh9bc97mnpm3ra